SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ziopharm Oncology Inc – ‘8-K’ for 6/17/15

On:  Friday, 6/19/15, at 5:18pm ET   ·   For:  6/17/15   ·   Accession #:  1193125-15-229022   ·   File #:  1-33038

Previous ‘8-K’:  ‘8-K’ on / for 6/18/15   ·   Next:  ‘8-K’ on / for 8/10/15   ·   Latest:  ‘8-K’ on 2/22/24 for 2/15/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/19/15  Ziopharm Oncology Inc             8-K:5       6/17/15    1:19K                                    RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     15K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  Form 8-K  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 17, 2015

 

 

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-33038   84-1475672

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One First Avenue, Parris Building 34, Navy Yard Plaza

Boston, Massachusetts

  02129
(Address of Principal Executive Offices)   (Zip Code)

(617) 259-1970

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

ZIOPHARM Oncology, Inc., or the Company, held its annual meeting of stockholders on June 17, 2015, at which all proposals brought before the meeting and requiring approval were approved by the requisite vote. The votes with respect to each proposal are set forth below.

(i) The stockholders elected five directors to serve as members of the Company’s board of directors until the next annual meeting of the stockholders. The stockholders present in person or by proxy cast the following numbers of votes in connection with the election of directors, resulting in the election of all director nominees:

 

Nominee

   Votes For      Votes Withheld      Broker Non-Votes  

Sir Murray Brennan, M.D., GNZM

     49,892,156         725,333         48,906,938   

James A. Cannon

     50,095,710         521,779         48,906,938   

Senator Wyche Fowler, Jr.

     49,890,410         727,079         48,906,938   

Randal J. Kirk

     49,898,701         718,788         48,906,938   

Michael Weiser, M.D., Ph.D.

     50,108,280         509,209         48,906,938   

(ii) The stockholders ratified the appointment of McGladrey LLP as the independent registered public accounting firm of the Company for 2015. There were 99,140,197 votes cast for the proposal; 246,223 votes were cast against the proposal; 138,007 votes abstained; and there were no broker non-votes.

(iii) The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the 2015 annual meeting. There were 49,285,721 votes cast for the proposal; 873,763 votes were cast against the proposal; 458,005 votes abstained; and there were 48,906,938 broker non-votes.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ZIOPHARM Oncology, Inc.
By:

/s/ Kevin G. Lafond

Date: June 19, 2015

Name: Kevin G. Lafond
Title: Vice President, Chief Accounting Officer and Treasurer

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:6/19/15
For Period End:6/17/15DEF 14A
 List all Filings 
Top
Filing Submission 0001193125-15-229022   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 7:33:34.2pm ET